Key result
Progestin-only and LARC methods offer safe contraception in high thrombosis risk, while estrogen options remain contraindicated.
Answers are grounded in this paper and cite their sources.
Managing contraception for women at high risk for thrombosis poses unique challenges. Combined estrogen and progestin contraceptives increase the risk of both venous and arterial thrombosis. They are contraindicated in women with a history of thrombosis and in other women at high risk for thrombosis. However, progestin-only contraceptives are generally considered safe in this patient population. This paper reviews the evidence linking hormonal contraception and clotting risk, outlines appropriate contraceptive methods for women at high risk for thrombosis, discusses surgical risk for sterilization in the setting of current or past thrombosis, and includes a review of the safety of hormonal methods for women who are fully anticoagulated. In general, long-acting reversible contraception is safe for women with a history of thrombosis and may offer additional noncontraceptive benefits for women who are on anticoagulant therapy, such as improved bleeding profiles.
No takes yet. Share an insight, caveat, or question.
Gray et al. (2018) conducted a review in High risk of thrombosis or history of thrombosis. Progestin-only and long-acting reversible contraception vs. Combined estrogen and progestin contraceptives was evaluated on Risk of venous and arterial thrombosis. Progestin-only and long-acting reversible contraceptives are generally safe for women at high risk for thrombosis, whereas combined estrogen-progestin contraceptives are contraindicated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: